{"id":263878,"date":"2026-01-29T15:29:13","date_gmt":"2026-01-29T15:29:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/263878\/"},"modified":"2026-01-29T15:29:13","modified_gmt":"2026-01-29T15:29:13","slug":"is-this-asx-healthcare-stock-a-buy-after-yesterdays-5-drop","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/263878\/","title":{"rendered":"Is this ASX healthcare stock a buy after yesterday&#8217;s 5% drop?"},"content":{"rendered":"<p><img width=\"1200\" height=\"675\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/01\/health-26-16.9-1200x675.jpeg\" class=\"attachment-full size-full wp-post-image\" alt=\"Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.\" decoding=\"async\" fetchpriority=\"high\"  \/><\/p>\n<p>Image source: Getty Images<\/p>\n<p>Saluda Medical Inc (<a class=\"tickerized-link\" href=\"https:\/\/www.fool.com.au\/tickers\/asx-sld\/\" rel=\"nofollow noopener\" target=\"_blank\">ASX: SLD<\/a>) is a recently listed ASX healthcare stock.\u00a0<\/p>\n<p>It is a commercial-stage medical device company commercialising spinal cord stimulation (SCS) therapy.\u00a0<\/p>\n<p>Saluda is currently a single product company, centred around its differentiated SCS product called the <a href=\"https:\/\/www.saludamedical.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">&#8216;Evoke System&#8217;<\/a>.<\/p>\n<p>It is designed for the treatment of patients with chronic pain of the trunk and\/or limbs.<\/p>\n<p> A bumpy ride\u00a0 <\/p>\n<p>Since initially listing in December last year, this <a href=\"https:\/\/www.fool.com.au\/investing-education\/small-cap\/\" rel=\"nofollow noopener\" target=\"_blank\">small-cap<\/a> ASX healthcare stock has experienced <a href=\"https:\/\/www.fool.com.au\/definitions\/volatility\/\" rel=\"nofollow noopener\" target=\"_blank\">volatility<\/a>.<\/p>\n<p>After opening at $1.27, the company saw its share price rocket 20% higher within the first week of trading.\u00a0<\/p>\n<p>However after topping out at $1.54, it has tumbled more than 26%.\u00a0<\/p>\n<p>This included a fall of more than 5% yesterday.<\/p>\n<p>It now sits close to an all-time low at $1.13.\u00a0<\/p>\n<p>It&#8217;s important to acknowledge that small-cap stocks can often experience increased volatility.\u00a0<\/p>\n<p> First update since December\u00a0 <\/p>\n<p>Yesterday, the company released its first <a href=\"https:\/\/www.fool.com.au\/tickers\/asx-sld\/announcements\/2026-01-28\/2a1649894\/quarterly-activities-appendix-4c-cash-flow-report\/\" rel=\"nofollow noopener\" target=\"_blank\">financial update<\/a> since its <a href=\"https:\/\/www.fool.com.au\/definitions\/initial-public-offering\/#:~:text=An%20initial%20public%20offering%20(IPO)%20is%20when%20a%20private%20company,public%20for%20the%20first%20time.\" rel=\"nofollow noopener\" target=\"_blank\">IPO<\/a> last December.\u00a0<\/p>\n<p>The company reported 1H26 revenue of $39.4m (+17% on pcp).\u00a0<\/p>\n<p>In a report from Bell Potter yesterday, the broker said the biggest positive was strong Q2 sales of $15.4m in the US (+17% on pcp and +19% qoq) driven by a greater number of physicians utilising the Evoke System.\u00a0<\/p>\n<p>International sales are a smaller contribution compared to the key US market but also increased during 1H26 to $11.0m (+26% on pcp).<\/p>\n<p>Bell Potter said this reflected strong execution on commercial targets as the company beat its 1H26 revenue forecast. This resulted in an upgraded FY26 revenue guidance by 4% to $85m.\u00a0<\/p>\n<p> Buy recommendation for this ASX healthcare stock <\/p>\n<p>The broker increased FY26 forecasts in line with the updated guidance while leaving FY27 and FY28 effectively unchanged.\u00a0<\/p>\n<p>Bell Potter said penetration into the US physician base is deepening and total volumes will benefit from the ongoing expansion and training of Saluda&#8217;s US sales force, which is proceeding at good pace.\u00a0<\/p>\n<p>Updated forecasts imply 2H26 global revenue growth of +25% on the pcp, with the most relevant focus being US sales, which we now expect to reach $34.2m in 2H26 at a growth rate of +37% on the pcp.<\/p>\n<p>The broker has retained its speculative buy recommendation on this ASX healthcare stock and slightly decreased its price target to $2.70 (previously $2.80).\u00a0<\/p>\n<p>From yesterday&#8217;s closing price of $1.13, this indicates an upside of 138.94%.\u00a0<\/p>\n<p>We maintain our BUY (speculative) recommendation and look forward to accelerating market share capture of the crucial US market over the coming reporting periods.<\/p>\n","protected":false},"excerpt":{"rendered":"Image source: Getty Images Saluda Medical Inc (ASX: SLD) is a recently listed ASX healthcare stock.\u00a0 It is&hellip;\n","protected":false},"author":2,"featured_media":263879,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46],"class_list":{"0":"post-263878","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-il","11":"tag-israel"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/263878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=263878"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/263878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/263879"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=263878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=263878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=263878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}